Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

You may be eligible if

• Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder
• * Recurrent or progressive low-grade B-cell lymphoma with at least one prior chemotherapy regimen (may have included monoclonal antibody)
• * Relapsed intermediate-grade or high-grade B-cell lymphoma or B-lineage acute lymphoblastic leukemia and patient not a candidate for, refused, or failed prior hematopoietic stem cell transplantation
• No chronic lymphocytic leukemia or lymphoma with more than 5,000/mm3circulating lymphoma cells
• Measurable or evaluable disease
• Must have failed standard curative therapy
• No CNS or leptomeningeal metastasis
• Performance status - Karnofsky 70-100%
• Performance status - ECOG 0-1
• At least 4 months
• Absolute neutrophil count at least 1,000/mm\^3
• Hemoglobin at least 10 g/dL (transfusion allowed)
• Platelet count at least 50,000/mm\^3
• AST no greater than upper limit of normal (ULN)
• Bilirubin no greater than 1.5 times ULN
• Hepatitis B surface antigen negative
• Creatinine no greater than ULN
• No prior unstable coronary artery disease
• No New York Heart Association class III or IV congestive heart failure
• DLCO and FEV1 at least 50% of predicted
• HIV negative
• No other concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
• No infection requiring IV antibiotic therapy within the past 4 weeks
• No other major illness that would preclude study
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• See Disease Characteristics
• Prior antibody therapy allowed
• Prior interleukin-2 or interferon alfa allowed
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy
• At least 4 weeks since prior systemic corticosteroids
• At least 4 weeks since prior radiotherapy
• At least 4 weeks since prior surgery